Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2021

01-08-2021 | ß-Blockers | Research Article

Guideline-led prescribing to ambulatory heart failure patients in a cardiology outpatient service

Authors: Seif El Hadidi, Carl Vaughan, David Kerins, Stephen Byrne, Ebtissam Darweesh, Margaret Bermingham

Published in: International Journal of Clinical Pharmacy | Issue 4/2021

Login to get access

Abstract

Background Guidelines recommend heart failure (HF) patients be treated with multiple medications at doses proven to improve clinical outcomes. Objective To study guideline-led prescribing in an Irish outpatient HF population. Setting Cardiology Outpatient Clinic, Mercy University Hospital, Cork, Ireland. Methods Guideline-led prescribing was assessed using the Guideline Adherence Index (GAI-3), that considered the prescribing of ACE inhibitors and angiotensin receptor blockers; beta-blockers and mineralocorticoid receptor antagonists. The GAI-based target dose was calculated based on the prescription of ≥ 50% of the guideline-recommended target dose of each of the three GAI medications to HF patients with ejection fraction ≤ 40%. High-GAI was achieved by prescription of ≥ 2 GAI medicines. Potentially inappropriate prescribing was assessed using a HF-specific tool. Main outcome measure Heart failure guideline-led prescribing assessed using the GAI-3. Results A total of 127 HF patients, mean age 71.7 ± 13.1 years, were identified in the study. Seventy-one patients had ejection fraction ≤ 40%. Population mean GAI-3 was 65.8%. When contraindications to therapy are considered, the adjusted GAI-3 increased to 72.9%. The target dose GAI was 18.5%. High-GAI management was prescribed to 54 patients (76.1%). A potentially inappropriate medicine in HF was prescribed to 14 (19.7%) patients. Conclusion Most HF patients with ejection fraction ≤ 40% in this setting received optimal guideline-led prescribing however the proportion of patients achieving the target doses of these agents was suboptimal.
Literature
1.
go back to reference McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC 2012 Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2012;33:1787–847.PubMedCrossRef McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC 2012 Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2012;33:1787–847.PubMedCrossRef
2.
go back to reference Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–200.PubMedCrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–200.PubMedCrossRef
3.
go back to reference Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS, et al. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19:1414–23.PubMedCrossRef Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS, et al. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017;19:1414–23.PubMedCrossRef
4.
go back to reference Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883–90.PubMedCrossRef Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017;38:1883–90.PubMedCrossRef
5.
go back to reference Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–66.PubMedCrossRef Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72:351–66.PubMedCrossRef
6.
go back to reference Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ, et al. Medication dosing for heart failure with reduced ejection fraction: opportunities and challenges. Eur J Heart Fail. 2019;21:286–96.PubMedCrossRef Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ, et al. Medication dosing for heart failure with reduced ejection fraction: opportunities and challenges. Eur J Heart Fail. 2019;21:286–96.PubMedCrossRef
7.
go back to reference Mogensen UM, Ersboll M, Andersen M, Andersson C, Hassager C, Torp-Pedersen C, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail. 2011;13:1216–23.PubMedCrossRef Mogensen UM, Ersboll M, Andersen M, Andersson C, Hassager C, Torp-Pedersen C, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail. 2011;13:1216–23.PubMedCrossRef
8.
go back to reference Hassanein M, Abdelhamid M, Ibrahim B, Sobhy M, Nasr G, Aboleineen MW, et al. Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long-Term Registry. ESC Heart Fail. 2018;5:1159–64.PubMedPubMedCentralCrossRef Hassanein M, Abdelhamid M, Ibrahim B, Sobhy M, Nasr G, Aboleineen MW, et al. Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long-Term Registry. ESC Heart Fail. 2018;5:1159–64.PubMedPubMedCentralCrossRef
9.
go back to reference Gilstrap LG, Stevenson LW, Small R, Parambi R, Hamershock R, Greenberg J, et al. Reasons for guideline non-adherence at heart failure discharge. J Am Heart Assoc. 2018;7(15):e008789.PubMedPubMedCentralCrossRef Gilstrap LG, Stevenson LW, Small R, Parambi R, Hamershock R, Greenberg J, et al. Reasons for guideline non-adherence at heart failure discharge. J Am Heart Assoc. 2018;7(15):e008789.PubMedPubMedCentralCrossRef
10.
go back to reference Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167:2695–9.PubMedCrossRef Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, et al. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol. 2013;167:2695–9.PubMedCrossRef
11.
go back to reference Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, et al. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation. 2015;132:1347–53.PubMedPubMedCentralCrossRef Allen LA, Fonarow GC, Liang L, Schulte PJ, Masoudi FA, Rumsfeld JS, et al. Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures. Circulation. 2015;132:1347–53.PubMedPubMedCentralCrossRef
12.
go back to reference Caughey GE, Roughead EE, Shakib S, Vitry AI, Gilbert AL. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, cross-sectional study of administrative claims data. Drugs Aging. 2011;28:575–81.PubMedCrossRef Caughey GE, Roughead EE, Shakib S, Vitry AI, Gilbert AL. Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, cross-sectional study of administrative claims data. Drugs Aging. 2011;28:575–81.PubMedCrossRef
13.
go back to reference Baron-Franco B, McLean G, Mair FS, Roger VL, Guthrie B, Mercer SW. Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e314–20.PubMedPubMedCentralCrossRef Baron-Franco B, McLean G, Mair FS, Roger VL, Guthrie B, Mercer SW. Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care. Br J Gen Pract. 2017;67(658):e314–20.PubMedPubMedCentralCrossRef
14.
go back to reference Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–69.PubMedCrossRef Page RL, O’Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–69.PubMedCrossRef
15.
go back to reference Bermingham M, Ryder M, Travers B, Edwards N, Lalor L, Kelly D, et al. The St Vincent’s potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. Eur J Heart Fail. 2014;16:915–22.PubMedCrossRef Bermingham M, Ryder M, Travers B, Edwards N, Lalor L, Kelly D, et al. The St Vincent’s potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. Eur J Heart Fail. 2014;16:915–22.PubMedCrossRef
16.
go back to reference Caughey GE, Shakib S, Barratt JD, Roughead EE. Use of medicines that may exacerbate heart failure in older adults: therapeutic complexity of multimorbidity. Drugs Aging. 2019;36:471–9.PubMedCrossRef Caughey GE, Shakib S, Barratt JD, Roughead EE. Use of medicines that may exacerbate heart failure in older adults: therapeutic complexity of multimorbidity. Drugs Aging. 2019;36:471–9.PubMedCrossRef
17.
go back to reference Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26:1653–9.PubMedCrossRef Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J. 2005;26:1653–9.PubMedCrossRef
18.
go back to reference Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail. 2008;10:1236–45.PubMedCrossRef Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail. 2008;10:1236–45.PubMedCrossRef
19.
go back to reference Deticek A, Locatelli I, Roblek T, Mrhar A, Lainscak M. Therapy modifications during hospitalization in patients with chronic heart failure. Eur J Int Med. 2016;29:52–8.CrossRef Deticek A, Locatelli I, Roblek T, Mrhar A, Lainscak M. Therapy modifications during hospitalization in patients with chronic heart failure. Eur J Int Med. 2016;29:52–8.CrossRef
21.
go back to reference Peters-Klimm F, Muller-Tasch T, Schellberg D, Remppis A, Barth A, Holzapfel N, et al. Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol. 2008;97:244–52.PubMedCrossRef Peters-Klimm F, Muller-Tasch T, Schellberg D, Remppis A, Barth A, Holzapfel N, et al. Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol. 2008;97:244–52.PubMedCrossRef
22.
go back to reference Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T. General practitioners’ adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol. 2016;105:441–50.PubMedCrossRef Hirt MN, Muttardi A, Helms TM, van den Bussche H, Eschenhagen T. General practitioners’ adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol. 2016;105:441–50.PubMedCrossRef
23.
go back to reference Barnett NL, Oboh L, Smith K. Patient-centred management of polypharmacy: a process for practice. Eur J Hosp Pharm. 2016;23:113–7.PubMedCrossRef Barnett NL, Oboh L, Smith K. Patient-centred management of polypharmacy: a process for practice. Eur J Hosp Pharm. 2016;23:113–7.PubMedCrossRef
24.
go back to reference El Hadidi S, Darweesh E, Byrne S, Bermingham M. A tool for assessment of heart failure prescribing quality: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2018;27:685–94.PubMedCrossRef El Hadidi S, Darweesh E, Byrne S, Bermingham M. A tool for assessment of heart failure prescribing quality: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2018;27:685–94.PubMedCrossRef
25.
go back to reference Poelzl G, Altenberger J, Pacher R, Ebner CH, Wieser M, Winter A, et al. Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014;175:83–9.PubMedCrossRef Poelzl G, Altenberger J, Pacher R, Ebner CH, Wieser M, Winter A, et al. Dose matters! Optimisation of guideline adherence is associated with lower mortality in stable patients with chronic heart failure. Int J Cardiol. 2014;175:83–9.PubMedCrossRef
26.
go back to reference Frankenstein L, Remppis A, Fluegel A, Doesch A, Katus HA, Senges J, et al. The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. Eur J Heart Fail. 2010;12:574–80.PubMedCrossRef Frankenstein L, Remppis A, Fluegel A, Doesch A, Katus HA, Senges J, et al. The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. Eur J Heart Fail. 2010;12:574–80.PubMedCrossRef
27.
go back to reference Oertle M, Bal R. Understanding non-adherence in chronic heart failure: a mixed-method case study. Qual Saf Health Care. 2010;19(6):e37.PubMed Oertle M, Bal R. Understanding non-adherence in chronic heart failure: a mixed-method case study. Qual Saf Health Care. 2010;19(6):e37.PubMed
28.
go back to reference Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20:1326–34.PubMedCrossRef Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstrom U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2018;20:1326–34.PubMedCrossRef
29.
go back to reference Ferreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail. 2017;19:1284–93.PubMedCrossRef Ferreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. Eur J Heart Fail. 2017;19:1284–93.PubMedCrossRef
30.
go back to reference Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.PubMedCrossRef
32.
go back to reference Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial. JACC Heart Fail. 2016;4:109–15.PubMedCrossRef Fiuzat M, Wojdyla D, Pina I, Adams K, Whellan D, O’Connor CM. Heart rate or beta-blocker dose? Association with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION trial. JACC Heart Fail. 2016;4:109–15.PubMedCrossRef
33.
go back to reference Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–8.PubMedCrossRef Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312–8.PubMedCrossRef
34.
go back to reference Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–8.PubMedCrossRef Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840–8.PubMedCrossRef
35.
go back to reference Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7:350–8.PubMedPubMedCentralCrossRef Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7:350–8.PubMedPubMedCentralCrossRef
36.
go back to reference Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a maximally tolerated beta-blocker dose in heart failure patients: is there room for improvement? J Am Coll Cardiol. 2017;69:2542–50.PubMedCrossRef Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a maximally tolerated beta-blocker dose in heart failure patients: is there room for improvement? J Am Coll Cardiol. 2017;69:2542–50.PubMedCrossRef
38.
go back to reference Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail. 2004;6:235–43.PubMedCrossRef Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail. 2004;6:235–43.PubMedCrossRef
39.
go back to reference Tebbe U, Tschope C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol. 2014;103:665–73.PubMedCrossRef Tebbe U, Tschope C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol. 2014;103:665–73.PubMedCrossRef
40.
go back to reference Hancock HC, Close H, Fuat A, Murphy JJ, Hungin AP, Mason JM. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open. 2014;4(3):e003866.PubMedPubMedCentralCrossRef Hancock HC, Close H, Fuat A, Murphy JJ, Hungin AP, Mason JM. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open. 2014;4(3):e003866.PubMedPubMedCentralCrossRef
41.
go back to reference Steinman MA, Dimaano L, Peterson CA, Heidenreich PA, Knight SJ, Fung KZ, et al. Reasons for not prescribing guideline-recommended medications to adults with heart failure. Med Care. 2013;51:901–7.PubMedPubMedCentralCrossRef Steinman MA, Dimaano L, Peterson CA, Heidenreich PA, Knight SJ, Fung KZ, et al. Reasons for not prescribing guideline-recommended medications to adults with heart failure. Med Care. 2013;51:901–7.PubMedPubMedCentralCrossRef
42.
go back to reference Mockler M, O’Loughlin C, Murphy N, Ryder M, Conlon C, McDonald KM, et al. Causes and consequences of nonpersistence with heart failure medication. Am J Cardiol. 2009;103:834–8.PubMedCrossRef Mockler M, O’Loughlin C, Murphy N, Ryder M, Conlon C, McDonald KM, et al. Causes and consequences of nonpersistence with heart failure medication. Am J Cardiol. 2009;103:834–8.PubMedCrossRef
43.
go back to reference Lopez Cabezas C, Falces Salvador C, Cubi Quadrada D, Arnau Bartes A, Ylla Bore M, Muro Perea N, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm Hosp. 2006;30:328–42.PubMedCrossRef Lopez Cabezas C, Falces Salvador C, Cubi Quadrada D, Arnau Bartes A, Ylla Bore M, Muro Perea N, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm Hosp. 2006;30:328–42.PubMedCrossRef
44.
go back to reference Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, et al. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2012;33:314–24.PubMedCrossRef Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, et al. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2012;33:314–24.PubMedCrossRef
45.
go back to reference Bhat S, Kansal M, Kondos GT, Groo V. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. Ann Pharmacother. 2018;52:724–32.PubMedCrossRef Bhat S, Kansal M, Kondos GT, Groo V. Outcomes of a pharmacist-managed heart failure medication titration assistance clinic. Ann Pharmacother. 2018;52:724–32.PubMedCrossRef
Metadata
Title
Guideline-led prescribing to ambulatory heart failure patients in a cardiology outpatient service
Authors
Seif El Hadidi
Carl Vaughan
David Kerins
Stephen Byrne
Ebtissam Darweesh
Margaret Bermingham
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-020-01220-z

Other articles of this Issue 4/2021

International Journal of Clinical Pharmacy 4/2021 Go to the issue